MADRID - Some volunteers have quit Johnson & Johnson’s COVID-19 vaccine trial in Spain after news of side effects in a participant in AstraZeneca’s trial, the Spanish programme’s lead investigator told Reuters on Tuesday.
“Many have called to ask us some more detail about the risk of the vaccine, whether what happened with that vaccine had anything to do with the one we are studying, these types of questions,” Borobia said.AstraZeneca’s COVID-19 vaccine trials were placed on hold worldwide on Sept. 6 after a serious side effect was reported in one volunteer in Britain.
Trials are also being carried out in the Netherlands and Germany, taking the total number of participants in all three countries to 550. If some doses and schedules generate considerable amounts of antibodies, an intermediate Phase III analysis could be conducted before the end of Phase II, Borobia said.
AstraZeneca 'scare' hahaha! you mean the real 'dodgy, unknown, sometimes severe side effects' 'scaremongering!' lmao
COVID-19 is the CCPVirus , it's a human-modified bioweapon that made in the lab.
uh oh
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Exclusive: AstraZeneca COVID-19 vaccine trial in U.S. on hold until at least midweek - sourcesAstraZeneca's COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a serious side effect in Britain even as other trials of the vaccine resume, sources familiar with the details told Reuters. There seems to be two 'Americas.' One - white, culturally 'Southern,' racist, still believes in the southern racial hierarchy that existed before emancipation. The other - diverse, working-class, culturally more 'Northern,' multicultural and multiracial. Which do you want? The US will always act in the best interests of its indigenous companies. It comes as no surprise .
Source: Reuters - 🏆 2. / 97 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: USATODAY - 🏆 100. / 63 Read more »